Source Post

A decades-old problem nobody could solve is finally breaking, and most people still haven’t caught on. Comm...

This reel highlights Nasus Pharma (NSRX) as a small-cap biotech stock under $3, focusing on its innovative needle-free epinephrine nasal powder delivery system for anaphylaxis treatment. The video contrasts this with traditional auto-injectors, emphasizing improved efficacy, convenience, and patient experience.